# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 2461-2470 of 2745 results.
Pancreatic Cancer Genetics
Status: Unknown status
Last Changed: Jul 03, 2015
First Received: Apr 13, 2010
Disease(s): Pancreatic Cancer
Locations: Columbia University Medical Center, New York, New York, United States
A Study of MORAb-202 in Participants With Solid Tumors
Status: Recruiting
Last Changed: May 29, 2020
First Received: Dec 29, 2017
Disease(s): Solid Tumors
Intervention(s): MORAb-202
Locations: Eisai Trial Site 5, Matsuyama City, Ehime, Japan
Eisai Trial Site 6, Kurume City, Fukuoka, Japan
Eisai Trial Site 8, Sapporo City, Hokkaido, Japan
Eisai Trial Site 4, Akashi-city, Hyogo, Japan
Eisai Trial Site 7, Niigata City, Niigata, Japan
... and 4 other locations.
A Study of LY3435151 in Participants With Solid Tumors
Status: Terminated
Last Changed: Apr 15, 2020
First Received: Sep 23, 2019
Disease(s): Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Cervical Carcinoma, High Grade Serous Ovarian Carcinoma, Hepatocellular Carcinoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma
Intervention(s): LY3435151, Pembrolizumab
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas, United States
National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Status: Recruiting
Last Changed: Oct 22, 2020
First Received: Nov 11, 2015
Disease(s): Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features, Synovial Sarcoma, INI1-negative Tumors, Malignant Rhabdoid Tumor of Ovary, Renal Medullary Carcinoma, Epithelioid Sarcoma, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Any Solid Tumor With an EZH2 GOF Mutation
Intervention(s): Tazemetostat
Locations: University of California San Francisco, San Francisco, California, United States
University of Colorado Denver, Aurora, Colorado, United States
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Northwestern Memorial Hospital, Chicago, Illinois, United States
Massachusetts General Hospital - Cancer Center, Boston, Massachusetts, United States
... and 28 other locations.
CPR Decision Aid For Patients With Advanced Gynecologic Malignancies
Status: Completed
Last Changed: Aug 19, 2019
First Received: Aug 16, 2017
Disease(s): Advance Care Planning
Intervention(s): video, usual care
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Status: Unknown status
Last Changed: Jun 24, 2015
First Received: Jan 31, 2014
Disease(s): Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy
Intervention(s): onapristone
Locations: Centre Oscar Lambret, Lille, France
Institut Curie Oncologie Medicale, Paris, France
Institut Gustave Roussy, Villejuif, France
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Status: Recruiting
Last Changed: Sep 17, 2020
First Received: Sep 25, 2013
Disease(s): Mesothelioma, Thymoma, Pancreatic Neoplasms, Biliary Tract Neoplasms, Stomach Neoplasms
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Status: Recruiting
Last Changed: Jun 25, 2020
First Received: Aug 03, 2017
Disease(s): Advanced Solid Tumor
Intervention(s): Pembrolizumab, Trebananib
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
High-dose Periop Statins for Prevention of DVT
Status: Completed
Last Changed: Dec 01, 2016
First Received: Nov 29, 2005
Disease(s): Gynecologic Oncological Pelvic/Abdominal Surgery
Intervention(s): atorvastatin
Locations: Yale-New Haven Hospital, New Haven, Connecticut, United States
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Status: Terminated
Last Changed: Jun 04, 2020
First Received: Jul 20, 2016
Disease(s): Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Kidney Neoplasms, Metastatic Renal Cell Carcinoma, Ovarian Clear Cell Carcinoma
Intervention(s): CDX-014
Locations: HonorHealth Research Institute, Scottsdale, Arizona, United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
... and 1 other locations.